Abstract: The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

Abstract: The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

Abstract: The present invention provides a protective formulation that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes. The formulation comprises a protective amount of live MG strain K5054 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

Abstract: The present invention provides a protective formulation that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes. The formulation comprises a protective amount of live MG strain K5054 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

Abstract: The present invention relates to the identification and purification of antigens from M. gallisepticum and M. synoviae and their use in serological assays. Cell proteins from these organisms that possess substantial immunoreactive responses with poultry antisera to the mycoplasma from which they are isolated in both the acute and convalescent stages of infection are identified. Of these immunogenic proteins, those that also lack immunogenic cross-reactivity with antisera to other poultry mycoplasmas and pathogens are identified. These species specific proteins are purified and incorporated into enzyme-linked immunosorbent assays (ELISAs). The resulting assays are able to detect sensitively and selectively both field or experimentally-induced M. gallisepticum or M. synoviae infection in poultry. A combination of these assays are incorporated into a diagnostic kit to allow the rapid, sensitive, and selective testing for and differentiation between M. gallisepticum and M. synoviae.